1-5 of 5
Manja Friese-Hamim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models

Manja Friese-Hamim, Maria J. Ortiz Ruiz, Olga Bogatyrova, Marina Keil, Felix Rohdich, Beatrix Blume, Birgitta Leuthner, Frank Czauderna, Diane Hahn, Julia Jabs, Frank Jaehrling, Timo Heinrich, Roland Kellner, Katherine Chan, Amy H.Y. Tong, Dirk Wienke, Jason Moffat, Andree Blaukat, Frank T. Zenke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 159–173.
https://doi.org/10.1158/1535-7163.MCT-23-0102
Published: 01 February 2024
View article titled, Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Open the PDF for Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models in another window
Includes: Supplementary data
Journal Articles

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 833–843.
https://doi.org/10.1158/1535-7163.MCT-22-0537
Published: 05 July 2023
View article titled, The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations
Open the PDF for The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations in another window
Journal Articles

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models

Michael P. Sanderson, Manja Friese-Hamim, Gina Walter-Bausch, Michael Busch, Stefanie Gaus, Djordje Musil, Felix Rohdich, Ugo Zanelli, Sondra L. Downey-Kopyscinski, Constantine S. Mitsiades, Oliver Schadt, Markus Klein, Christina Esdar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1378–1387.
https://doi.org/10.1158/1535-7163.MCT-21-0005
Published: 01 August 2021
View article titled, M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
Open the PDF for M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models in another window
Includes: Supplementary data
Journal Articles

Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Lluís Nisa, Paola Francica, Roland Giger, Matúš Medo, Olgun Elicin, Manja Friese-Hamim, Claudia Wilm, Christopher Stroh, Beat Bojaxhiu, Aurélie Quintin, Marco D. Caversaccio, Matthias S. Dettmer, Mélanie Buchwalder, Tess M. Brodie, Daniel M. Aebersold, Yitzhak Zimmer, Thomas E. Carey, Michaela Medová
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 614–626.
https://doi.org/10.1158/1535-7163.MCT-18-1274
Published: 06 February 2020
View article titled, Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Open the PDF for Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B252: Identification of a new class of highly potent and selective c‐Met kinase inhibitors

Andree Blaukat, Friedhelm Bladt, Dieter Dorsch, Claus Fittschen, Manja Friese‐Hamim, Ulrich Graedler, Michael Meyring, Wilfried Rautenberg, Oliver Schadt, Frank Stieber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B252.
https://doi.org/10.1158/1535-7163.TARG-09-B252
Published: 10 December 2009
View article titled, Abstract B252: Identification of a new class of highly potent and selective c‐Met kinase inhibitors